Agios Announces Exercise of Over-Allotment Option in Public Offering
April 26, 2017 07:01 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that the underwriters of its previously announced public offering of common stock have...
Agios Announces Closing of Public Offering
April 24, 2017 16:01 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of 5,050,505...
Agios Announces Pricing of $250 Million Public Offering of Common Stock
April 18, 2017 20:34 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten a public offering of 5,050,505 shares of common...
Agios Announces Proposed Offering of Common Stock
April 17, 2017 16:01 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 4.5 million...
Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017
March 30, 2017 07:30 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene
March 13, 2017 07:30 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that Celgene Corporation has designated the development candidate focused on MTAP...
Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017
February 28, 2017 07:30 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
February 16, 2017 07:01 ET
|
Agios Pharmaceuticals
- Ivosidenib (AG-120) NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected in the Second Half of 2017 - - AG-348 Pivotal Trial Design Update Expected in...
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017
February 09, 2017 07:30 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017
January 09, 2017 07:30 ET
|
Agios Pharmaceuticals
- Enasidenib (AG-221) NDA Submitted for IDH2m Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - - AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017 - - AG-348 Advancing to...